Force E, Taberner F, Cabellos C, Ribes S, Doménech A, Tubau F, Viladrich P F, Gudiol F
Hospital Universitari de Bellvitge, Barcelona, Spain.
Eur J Clin Microbiol Infect Dis. 2009 Jul;28(7):807-11. doi: 10.1007/s10096-009-0711-y. Epub 2009 Feb 17.
Meropenem is a broad-spectrum carbapenem antibiotic that is highly active against the pathogens causing meningitis. The aims of this study was to determine the efficacies of meropenem alone and combined with rifampin against two Streptococcus pneumoniae strains with different susceptibility to beta-lactams using the guinea pig meningitis model and compare them with the standard ceftriaxone plus vancomycin therapy. All treatments except rifampin were bactericidal from 6 h. The addition of rifampin did not improve the activity of meropenem alone. Our results provide good evidence of the efficacy of meropenem in the treatment of penicillin- and cephalosporin-susceptible and -resistant pneumococcal meningitis similar to that of ceftriaxone plus vancomycin, suggesting that meropenem might be a good option in the management of this infection.
美罗培南是一种广谱碳青霉烯类抗生素，对引起脑膜炎的病原体具有高度活性。本研究的目的是使用豚鼠脑膜炎模型确定美罗培南单独使用以及与利福平联合使用对两种对β-内酰胺类药物敏感性不同的肺炎链球菌菌株的疗效，并将其与标准的头孢曲松加万古霉素治疗进行比较。除利福平外，所有治疗在6小时后均具有杀菌作用。添加利福平并没有提高美罗培南单独使用时的活性。我们的结果充分证明了美罗培南在治疗对青霉素和头孢菌素敏感及耐药的肺炎球菌脑膜炎方面的疗效与头孢曲松加万古霉素相似，这表明美罗培南可能是治疗这种感染的一个良好选择。
